Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Thermo Fisher boosts biologics in Europe and US

by Rick Mullin
October 9, 2021 | A version of this story appeared in Volume 99, Issue 37

 

A photo of a biologic-drug plant in Switzerland.
Credit: Thermo Fisher Scientific
Thermo Fisher already has its sign up on the former CSL plant.

Thermo Fisher Scientific has taken control of a biologic-drug production facility under construction in Lengnau, Switzerland, as part of a partnership with the facility’s previous owner, CSL. Thermo will make CSL’s hemophilia drug Idelvion when the plant opens next year and will eventually bring in other manufacturing customers. Separately, Thermo plans to spend $83 million to expand its biologic-drug facility in Saint Louis. The project is expected to create 169 jobs.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.